Marker Therapeutics Inc (MRKR)

[Phantom Lord]

Company has to apply for fast track before it can be granted. I won't be surprised if they eventually do get some fast track designations but I think this past year the primary focus was on getting the PII AML trial up and running. Obviously the surprise pancreatic data came out too so focus was moved there as well. Applying for fast track designations probably wasn't higher on the list of priorities than those two things.

As for why the primary focus is AML rather than lymphoma I can only assume it's due to the severity of AML. Five year survival of patients with lymphoma is ~71% while the five year survival of patients with AML is ~24%. AML patients have a lot less treatment options and their prognosis is typically a lot worse than those with lymphoma.

This is just my guess. I don't think the PII trial in lymphoma will be too far off. Depending on how much they get in the next round of funding I would think we see at least one more PII initiated next year.